008930:KRXHanmi Science Co., Ltd Analysis
Data as of 2026-06-04 - not real-time
₩32,150.00
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Hanmi Science is trading well below its 20‑day (≈33,900) and 50‑day (≈36,600) moving averages, with the price hovering near the 30,900 support level. The RSI of 38.6 and a bearish MACD histogram confirm a short‑term downtrend, while a 30‑day volatility of over 40% and a beta under 1 point to heightened price swings and modest market correlation.
On the fundamentals side, the company posts solid profitability (gross margin ~23%, ROE ~14.6%) and modest revenue growth of about 7% YoY, yet its debt‑to‑equity ratio exceeds 18, indicating a heavy leverage burden. The DCF‑derived fair value of roughly 1,800 KRW is far below the current 32,150 KRW price, suggesting the stock is significantly overvalued, though the modest 0.92% dividend yield appears sustainable given the low payout ratio and positive cash flow.
On the fundamentals side, the company posts solid profitability (gross margin ~23%, ROE ~14.6%) and modest revenue growth of about 7% YoY, yet its debt‑to‑equity ratio exceeds 18, indicating a heavy leverage burden. The DCF‑derived fair value of roughly 1,800 KRW is far below the current 32,150 KRW price, suggesting the stock is significantly overvalued, though the modest 0.92% dividend yield appears sustainable given the low payout ratio and positive cash flow.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- price below key moving averages and near support
- bearish MACD and sub‑50 RSI
- significant overvaluation versus DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- steady profitability and decent ROE
- low dividend payout supporting cash flow
- persistent high leverage and technical weakness
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- strong underlying earnings power and dividend sustainability
- potential valuation correction as market re‑prices debt risk
- defensive healthcare sector exposure
Key Metrics & Analysis
Financial Health
Revenue Growth6.70%
Profit Margin9.85%
ROE14.60%
ROA2.78%
Debt/Equity18.82
Op. Cash Flow₩57.6B
Free Cash Flow₩10.9B
Industry P/E27.2
Technical Analysis
TrendBearish
RSI38.6
Support₩30,900.00
Resistance₩38,400.00
MA 20₩33,917.50
MA 50₩36,563.00
MA 200₩38,849.50
MACDBearish
VolumeStable
Fear & Greed Index91.43
Valuation
Fair Value₩1,779.25
GradeOvervalued
TypeValue
Dividend Yield0.92%
Risk Assessment
Beta0.84
Volatility42.26%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.